Nektar Therapeutics (NKTR) Income towards Parent Company (2010 - 2026)

Nektar Therapeutics' Income towards Parent Company history runs 17 years deep, the most recent figure standing at -$43.2 million for Q1 2026.

• In Q1 2026, Income towards Parent Company rose 7.04% year-over-year to -$43.2 million; the TTM figure through Mar 2026 stood at -$152.1 million (down 18.27% YoY), while the FY2025 annual figure was -$155.3 million, down 30.58% from the prior year.
• Income towards Parent Company was -$43.2 million for Q1 2026 at Nektar Therapeutics, down from -$34.7 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $7.3 million in Q4 2024 to a low of -$159.1 million in Q2 2022.
• Historically, Income towards Parent Company has averaged -$56.5 million across 5 years, with a median of -$45.8 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Income towards Parent Company jumped 117.7% in 2024, then tumbled 579.01% in 2025.
• A 5-year view of Income towards Parent Company shows it stood at -$59.7 million in 2022, then jumped by 31.37% to -$41.0 million in 2023, then soared by 117.7% to $7.3 million in 2024, then sank by 579.01% to -$34.7 million in 2025, then decreased by 24.24% to -$43.2 million in 2026.
• The last three Income towards Parent Company figures came in at -$43.2 million (Q1 2026), -$34.7 million (Q4 2025), and -$35.0 million (Q3 2025), per Business Quant data.